Pfizer Inc. (NYSE:PFE) Shares Sold by Warner Financial Inc.

Warner Financial Inc. cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 46.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 20,510 shares of the biopharmaceutical company’s stock after selling 18,083 shares during the quarter. Warner Financial Inc.’s holdings in Pfizer were worth $544,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of PFE. Buffington Mohr McNeal acquired a new position in Pfizer during the 4th quarter worth $331,000. Diamant Asset Management Inc. grew its position in shares of Pfizer by 19.4% during the fourth quarter. Diamant Asset Management Inc. now owns 10,165 shares of the biopharmaceutical company’s stock worth $270,000 after buying an additional 1,650 shares in the last quarter. Cascade Investment Advisors Inc. raised its holdings in Pfizer by 5.4% in the fourth quarter. Cascade Investment Advisors Inc. now owns 63,144 shares of the biopharmaceutical company’s stock valued at $1,675,000 after acquiring an additional 3,235 shares in the last quarter. BankPlus Wealth Management LLC purchased a new position in Pfizer in the fourth quarter worth approximately $398,000. Finally, Lebenthal Global Advisors LLC increased its position in shares of Pfizer by 40.6% in the 4th quarter. Lebenthal Global Advisors LLC now owns 26,901 shares of the biopharmaceutical company’s stock valued at $714,000 after purchasing an additional 7,765 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 2.9 %

PFE opened at $26.86 on Tuesday. The stock’s fifty day moving average is $26.11 and its 200-day moving average is $27.94. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a market capitalization of $152.19 billion, a PE ratio of 36.29, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.17) EPS. On average, equities analysts predict that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.40%. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Insider Buying and Selling

In related news, Director Scott Gottlieb bought 1,000 shares of the firm’s stock in a transaction on Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This represents a 11.11 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.06% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Citigroup initiated coverage on Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price target for the company. Sanford C. Bernstein began coverage on shares of Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price for the company. Wolfe Research started coverage on shares of Pfizer in a research report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target for the company. Bank of America restated a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Finally, Evercore ISI raised Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.